Your browser is no longer supported. Please, upgrade your browser.
CBAY CymaBay Therapeutics, Inc. monthly Stock Chart
CBAY [NASD]
CymaBay Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.35 Insider Own0.62% Shs Outstand68.88M Perf Week3.10%
Market Cap265.18M Forward P/E- EPS next Y-0.99 Insider Trans0.00% Shs Float68.46M Perf Month104.28%
Income-92.80M PEG- EPS next Q-0.24 Inst Own85.70% Short Float12.29% Perf Quarter124.71%
Sales- P/S- EPS this Y-22.20% Inst Trans-0.39% Short Ratio2.48 Perf Half Y131.52%
Book/sh2.54 P/B1.50 EPS next Y-7.60% ROA-42.20% Target Price- Perf Year-66.49%
Cash/sh2.54 P/C1.51 EPS next 5Y- ROE-45.80% 52W Range1.21 - 12.49 Perf YTD94.90%
Dividend- P/FCF- EPS past 5Y10.40% ROI- 52W High-69.42% Beta1.41
Dividend %- Quick Ratio15.60 Sales past 5Y- Gross Margin- 52W Low215.70% ATR0.31
Employees24 Current Ratio15.60 Sales Q/Q- Oper. Margin- RSI (14)64.31 Volatility6.16% 8.54%
OptionableYes Debt/Eq0.00 EPS Q/Q49.00% Profit Margin- Rel Volume0.55 Prev Close3.85
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume3.39M Price3.82
Recom1.70 SMA205.05% SMA5056.93% SMA20022.12% Volume1,853,507 Change-0.78%
May-26-20Upgrade H.C. Wainwright Neutral → Buy $9
May-12-20Upgrade SVB Leerink Mkt Perform → Outperform $6
May-12-20Upgrade Stifel Hold → Buy $4 → $8
May-12-20Upgrade ROTH Capital Neutral → Buy $15
May-12-20Upgrade Raymond James Mkt Perform → Outperform $7
May-12-20Upgrade Evercore ISI In-line → Outperform $15
Mar-13-20Upgrade Oppenheimer Perform → Outperform $4
Mar-13-20Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-26-19Downgrade ROTH Capital Buy → Neutral $22 → $2
Nov-26-19Downgrade Raymond James Strong Buy → Mkt Perform
Nov-26-19Downgrade H.C. Wainwright Buy → Neutral $16 → $2
Nov-26-19Downgrade Cantor Fitzgerald Overweight → Neutral $20 → $2
Nov-25-19Downgrade SunTrust Buy → Hold
Nov-25-19Downgrade Stifel Buy → Hold
Nov-25-19Downgrade Evercore ISI Outperform → In-line
Jun-25-19Initiated Stifel Buy
Jun-12-19Upgrade Raymond James Outperform → Strong Buy
May-14-19Initiated Citigroup Buy $21
Feb-06-19Initiated B. Riley FBR Neutral $9
Jun-28-18Initiated Raymond James Outperform
Jun-05-20 05:00PM  
Jun-02-20 10:22AM  
Jun-01-20 08:34AM  
May-26-20 06:12PM  
May-21-20 07:21AM  
May-15-20 08:29AM  
May-13-20 09:37AM  
08:18AM  
May-12-20 03:20PM  
10:34AM  
09:45AM  
08:06AM  
02:20AM  
02:00AM  
May-11-20 04:01PM  
May-04-20 04:43PM  
Apr-02-20 04:01AM  
Mar-20-20 08:30PM  
10:44AM  
06:30AM  
Mar-13-20 05:29PM  
Mar-12-20 04:01PM  
02:30PM  
Mar-11-20 07:00PM  
Mar-10-20 12:15PM  
08:44AM  
Mar-09-20 07:51PM  
11:40AM  
10:57AM  
Mar-06-20 10:49AM  
Mar-05-20 07:00PM  
04:01PM  
01:30PM  
Mar-04-20 06:09PM  
Mar-03-20 03:12PM  
12:27PM  
11:00AM  
01:10AM  
Mar-02-20 06:50PM  
06:07PM  
04:15PM  
08:09AM  
Feb-28-20 09:52PM  
Feb-05-20 11:52AM  
Jan-29-20 04:15PM  
Jan-15-20 02:25PM  
Jan-10-20 09:21AM  
Dec-31-19 11:48AM  
Dec-17-19 10:31AM  
Dec-10-19 03:36PM  
Dec-09-19 06:09AM  
Dec-08-19 07:09PM  
Nov-29-19 11:24AM  
08:41AM  
Nov-27-19 10:09AM  
Nov-26-19 11:07AM  
08:24AM  
08:06AM  
Nov-25-19 04:20PM  
09:14AM  
08:47AM  
08:34AM  
08:00AM  
Nov-22-19 03:22PM  
Nov-14-19 08:00AM  
Nov-05-19 04:10PM  
Nov-04-19 08:00AM  
Nov-03-19 08:11AM  
Oct-28-19 08:00AM  
Oct-18-19 10:23AM  
Oct-14-19 08:00AM  
Oct-01-19 04:05PM  
Sep-30-19 08:00AM  
Sep-28-19 09:35AM  
Sep-17-19 04:30PM  
Sep-16-19 06:28AM  
Sep-10-19 03:31PM  
Sep-03-19 08:00AM  
Aug-23-19 12:36PM  
Aug-12-19 08:46AM  
Aug-09-19 02:01PM  
Aug-07-19 04:10PM  
Aug-05-19 08:00AM  
Jul-31-19 04:23PM  
Jun-18-19 08:00AM  
Jun-17-19 02:15PM  
10:08AM  
08:00AM  
Jun-13-19 11:51AM  
Jun-12-19 06:27PM  
09:27AM  
08:53AM  
07:34AM  
Jun-11-19 12:25PM  
09:02AM  
08:58AM  
08:30AM  
07:00AM  
Jun-10-19 02:50PM  
May-22-19 10:26AM  
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah SujalChief Executive OfficerOct 10Buy4.305,00021,500120,000Oct 15 08:20 AM
Shah SujalChief Executive OfficerSep 23Buy5.553,10017,205115,000Sep 24 08:56 AM
Shah SujalChief Executive OfficerSep 20Buy5.501,90010,450111,900Sep 24 08:56 AM